Research Peptides · Cat. 019-28
Urocortin III (Human)
Supplied as 100 µg per unit. Purity ≥ 95%. Molecular weight 4137.92. Species: Human. Technical values shown are imported catalog fields and should be confirmed against current documentation. Laboratory research use only.
Specifications
| Catalog number | 019-28 |
|---|---|
| Product type | Research Peptides |
| Peptide family | Urocortin |
| Species | Human |
| Unit size | 100 µg |
| Molecular weight | 4137.92 Da |
| Purity | ≥ 95% |
| Validation | Exhibits correct molecular weight |
| Appearance | White powder |
| Contents | Each vial contains 100 µg of NET peptide. Plasma urocortin levels in the diagnosis of ovarian endometriosis. Florio P, Reis FM, Torres PB, et al. Obstet Gynecol. 2007;110(3):594-600. High maternal and fetal plasma urocortin levels in pregnancies complicated by hypertension. Florio P, Torricelli M, De falco G, et al. J Hypertens. 2006;24(9):1831-40. Maternal plasma corticotrophin-releasing factor and urocortin levels in post-term pregnancies. Torricelli M, Ignacchiti E, Giovannelli A, et al. Eur J Endocrinol. 2006;154(2):281-5. Expression of urocortin 3/stresscopin in human adrenal glands and adrenal tumors. Takahashi K, Totsune K, Saruta M, et al. Peptides. 2006;27(1):178-82. High fetal urocortin levels at term and preterm labor. Florio P, Torricelli M, Galleri L, et al. J Clin Endocrinol Metab. 2005;90(9):5361-5. Urocortin 3/stresscopin in human colon: possible modulators of gastrointestinal function during stressful conditions. Saruta M, Takahashi K, Suzuki T, Fukuda T, Torii A, Sasano H. Peptides. 2005;26(7):1196-206. Expression of urocortin III/stresscopin in human heart and kidney. Takahashi K, Totsune K, Murakami O, et al. J Clin Endocrinol Metab. 2004;89(4):1897-903. Urocortin 1 in colonic mucosa in patients with ulcerative colitis. Saruta M, Takahashi K, Suzuki T, Torii A, Kawakami M, Sasano H. J Clin Endocrinol Metab. 2004;89(11):5352-61. Differential interactions of urocortin/corticotropin-releasing hormone peptides with the blood-brain barrier. Kastin AJ, Akerstrom V. Neuroendocrinology. 2002;75(6):367-74. Up-regulation of nitric oxide synthase and modulation of the guanylate cyclase activity by corticotropin-releasing hormone but not urocortin II or urocortin III in cultured human pregnant myometrial cells. Aggelidou E, Hillhouse EW, Grammatopoulos DK. Proc Natl Acad Sci USA. 2002;99(5):3300-5. |
| Solubility | Insoluble in water. Dissolve in 100-200 µl of DMSO. Then dilute with water or any desired buffer. |
| Intended use | In vitro laboratory research only — not for human or veterinary use, diagnostic or therapeutic purposes |
Sequence
Phe-Thr-Leu-Ser-Leu-Asp-Val-Pro-Thr-Asn-Ile-Met-Asn-Leu-Leu-Phe-Asn-Ile-Ala-Lys-Ala-Lys-Asn-Leu-Arg-Ala-Gln-Ala-Ala-Ala-Asn-Ala-His-Leu-Met-Ala-Gln-Ile-NH2
Storage & handling
Up to 6 months in lyophilized form at 0-5°C. For best results, rehydrate just before use. After rehydration, keep solution at +4°C for up to 5 days or freeze at -20°C for up to 3 months. Aliquot before freezing to avoid repeated freeze-thaw cycles.
Confirm handling and preparation requirements against current product documentation and the requirements of your laboratory protocol.
Frequently asked
What is Urocortin III (Human)?
What purity is listed for 019-28?
How should Urocortin III (Human) be stored?
What is the sequence of Urocortin III (Human)?
What is the intended use of 019-28?
This page reproduces an imported research-catalog record. Verify identity, specifications, documentation and suitability before purchase. The item is offered only for laboratory research and is not represented for human or veterinary use.